Trial Profile
A Retrospective, Multicentre study to evaluate the safety and efficacy of Vedolizumab in Austrian paediatric patients with Inflammatory bowel disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Oct 2018
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Therapeutic Use
- 25 Oct 2018 New trial record
- 15 Sep 2018 Results published in the BMC Gastroenterology